{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:38:47Z","timestamp":1778881127823,"version":"3.51.4"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Alveolar soft part sarcoma (ASPS) represent 0.5% of sarcomas, defining a rarest among rare malignancies. It affects young adults, displaying slow-growing mass of the thigh, head and neck, and trunk. Although quite indolent, a majority of cases displays an advanced disease with lung bone or central nervous system metastasis. Complete surgery is the cornerstone of localized ASPS, and advanced diseases poorly respond to chemotherapy. Here discuss recent progress in molecular characterization of ASPS and future prospects of therapeutic approaches.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>ASPS is characterized by a specific oncogenic translocation <jats:italic toggle=\"yes\">ASPSCR1<\/jats:italic>-<jats:italic toggle=\"yes\">TFE3<\/jats:italic> that induce <jats:italic toggle=\"yes\">hepatocyte growth factor receptor<\/jats:italic> (<jats:italic toggle=\"yes\">MET<\/jats:italic>) overexpression, angiogenesis, and immunosuppression in the tumor microenvironment. These specific biological features have encouraged the successful exploration of MET inhibitors, antiangiogenic drugs, and immunotherapy. We reviewed the main tracks of ASPS biology and recent insights from targeted therapies is ASPS mainly driven tyrosine kinase inhibitors (especially antiangiogenics), immune-checkpoint inhibitors, and their combinations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Overall, antiangiogenics and anti Programmed cell death 1\/Programmed cell death ligand 1 therapies showed a significant activity in ASPS that warrants additional investigation through randomized trials to validate those results and through ancillary biological studies to better understand resistance mechanisms and biomarkers of response.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cco.0000000000000652","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T04:17:58Z","timestamp":1590466678000},"page":"295-300","source":"Crossref","is-referenced-by-count":15,"title":["Novel therapeutic options for alveolar soft part sarcoma: antiangiogenic therapy, immunotherapy and beyond"],"prefix":"10.1097","volume":"32","author":[{"given":"Mehdi","family":"Brahmi","sequence":"first","affiliation":[{"name":"Department of Medical Oncology"},{"name":"Biology of Rares Sarcomas Team, Cancer Research Center of Lyon, Universit\u00e9 Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre L\u00e9on B\u00e9rard, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Vanacker","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armelle","family":"Dufresne","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,5,20]]},"reference":[{"key":"R1-20230901","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/cncr.31176","article-title":"Presentation and outcome of frequent and rare sarcoma histologic subtypes: a study of 10,262 patients with localized visceral\/soft tissue sarcoma managed in reference centers","volume":"124","author":"Penel","year":"2018","journal-title":"Cancer"},{"key":"R2-20230901","doi-asserted-by":"crossref","first-page":"e26953","DOI":"10.1002\/pbc.26953","article-title":"Alveolar soft part sarcoma in children and young adults: a report of 69 cases","volume":"65","author":"Flores","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"R3-20230901","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1158\/0008-5472.CAN-06-2855","article-title":"TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition","volume":"67","author":"Tsuda","year":"2007","journal-title":"Cancer Res"},{"key":"R4-20230901","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2407-9-22","article-title":"Gene expression profiling of alveolar soft-part sarcoma (ASPS)","volume":"9","author":"Stockwin","year":"2009","journal-title":"BMC Cancer"},{"key":"R5-20230901","doi-asserted-by":"crossref","first-page":"7314","DOI":"10.1158\/1078-0432.CCR-07-0174","article-title":"Angiogenesis-promoting gene patterns in alveolar soft part sarcoma","volume":"13","author":"Lazar","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R6-20230901","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/ni1378","article-title":"Transcription factors TFE3 and TFEB are critical for CD40 ligand expression and thymus-dependent humoral immunity","volume":"7","author":"Huan","year":"2006","journal-title":"Nat Immunol"},{"key":"R7-20230901","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/jso.24183","article-title":"Prognostic factors in alveolar soft part sarcoma: a SEER analysis","volume":"113","author":"Wang","year":"2016","journal-title":"J Surg Oncol"},{"key":"R8-20230901","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(06)70729-X","article-title":"Vascular-endothelial-growth factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma","volume":"7","author":"Azizi","year":"2006","journal-title":"Lancet Oncology"},{"key":"R9-20230901","doi-asserted-by":"crossref","first-page":"907179","DOI":"10.1155\/2012\/907179","article-title":"Alveolar soft part sarcoma: a single-center 26-patient case series and review of the literature","volume":"2012","author":"Ogura","year":"2012","journal-title":"Sarcoma"},{"key":"R10-20230901","doi-asserted-by":"crossref","first-page":"5894","DOI":"10.1002\/cncr.27582","article-title":"Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial","volume":"118","author":"Wagner","year":"2012","journal-title":"Cancer"},{"key":"R11-20230901","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/annonc\/mdx774","article-title":"Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 \u2018CREATE\u2019","volume":"29","author":"Sch\u00f6ffski","year":"2018","journal-title":"Ann Oncol"},{"key":"R12-20230901","doi-asserted-by":"crossref","first-page":"e13584","DOI":"10.1097\/MD.0000000000013584","article-title":"Effective treatment of advanced alveolar soft part sarcoma with sunitinib: a case report","volume":"97","author":"Ye","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"R13-20230901","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1634\/theoncologist.2017-0161","article-title":"Activity of pazopanib and trabectedin in advanced alveolar soft part sarcoma","volume":"23","author":"Stacchiotti","year":"2018","journal-title":"Oncologist"},{"key":"R14-20230901","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"R15-20230901","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1634\/theoncologist.2018-0464","article-title":"A phase II trial of pazopanib in patients with metastatic alveolar soft part sarcoma","volume":"24","author":"Kim","year":"2019","journal-title":"Oncologist"},{"key":"R16-20230901","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1158\/1078-0432.CCR-13-1881","article-title":"Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma","volume":"20","author":"Judson","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R17-20230901","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1470-2045(19)30215-3","article-title":"Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial","volume":"20","author":"Judson","year":"2019","journal-title":"Lancet Oncol"},{"key":"R18-20230901","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.2147\/CMAR.S198429","article-title":"The efficacy and safety of apatinib in metastatic alveolar soft part sarcoma: a case series of six patients in one institution","volume":"11","author":"Wang","year":"2019","journal-title":"Cancer Manag Res"},{"key":"R19-20230901","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1159\/000450545","article-title":"Metastatic alveolar soft part sarcoma responsive to pazopanib after progression through sunitinib and bevacizumab: two cases","volume":"9","author":"Read","year":"2016","journal-title":"Case Rep Oncol"},{"key":"R20-20230901","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1158\/2326-6066.CIR-18-0037","article-title":"Response to immune checkpoint inhibition in two patients with alveolar soft-part sarcoma","volume":"6","author":"Lewin","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"R21-20230901","first-page":"1","article-title":"Positive tumor response to combined checkpoint inhibitors in a patient with refractory alveolar soft part sarcoma: a case report","volume":"4","author":"Conley","year":"2018","journal-title":"J Glob Oncol"},{"key":"R22-20230901","article-title":"Complete response to dual immunotherapy in a young adult with metastatic alveolar soft part sarcoma enabled by a drug recovery program in a community practice","author":"Conry","year":"2019","journal-title":"J Adolesc Young Adult Oncol"},{"key":"R23-20230901","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s40425-017-0301-y","article-title":"Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials","volume":"5","author":"Groisberg","year":"2017","journal-title":"J Immunother Cancer"},{"key":"R25-20230901","doi-asserted-by":"crossref","first-page":"v517","DOI":"10.1093\/annonc\/mdz253.096","article-title":"High clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: First results of the AcS\u00e9 pembrolizumab study","volume":"30","author":"Blay","year":"2019","journal-title":"Annals of Oncology"},{"key":"R26-20230901","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"R27-20230901","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1470-2045(19)30153-6","article-title":"Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial","volume":"20","author":"Wilky","year":"2019","journal-title":"Lancet Oncol"},{"issue":"(18_Suppl)","key":"R28-20230901","doi-asserted-by":"crossref","first-page":"LBA-3","DOI":"10.1200\/JCO.2019.37.18_suppl.LBA3","article-title":"ANNOUNCE: a randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS)","volume":"37","author":"Tap","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T07:15:15Z","timestamp":1693552515000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,20]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000000652","relation":{},"ISSN":["1040-8746","1531-703X"],"issn-type":[{"value":"1040-8746","type":"print"},{"value":"1531-703X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,20]]}}}